Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Bone Marrow Sampling and Transplants

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...

Multipotency of Hematopoietic Stem Cells

Multipotency of Hematopoietic Stem Cells

The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...

Regulation of Hematopoietic Stem Cells

Regulation of Hematopoietic Stem Cells

All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...

Hematopoiesis

Hematopoiesis

The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...

Tissue Transplantation

Tissue Transplantation

Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...

Overview of Hematopoiesis

Overview of Hematopoiesis

Hematopoiesis, or blood cell production, is a vital biological process that begins early in embryonic development and continues throughout life. This process generates the various types of cells found in blood, including red blood cells, white blood cells, and platelets from hematopoietic stem cells (HSCs).
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Sebetralstat for on-demand treatment of hereditary angioedema: A pooled analysis of placebo-controlled clinical trials.

The World Allergy Organization journal·2026

Same author

[Common Variable Immunodeficiency as a Multisystem Disorder - A Case Report].

Harefuah·2026

Same author

Response to: 'Comment on 'Metagenomic next-generation sequencing: a game changer in the diagnosis of unique intraocular infections''.

Eye (London, England)·2026

Same author

Oral deucrictibant for on-demand treatment of hereditary angioedema attacks (RAPIDe-1): a randomised, double-blind, placebo-controlled, phase 2 trial.

The Lancet. Haematology·2026

Same author

Autoantibodies neutralizing type I IFNs in 40% of patients with WNV encephalitis in seven new cohorts.

Journal of human immunity·2026

Same author

Assessment of TREC-Based NBS SCID Reporting Practices for Harmonization of Results and Interpretation: A Global Survey.

The journal of allergy and clinical immunology. In practice·2026

Search research articles

Related Experiment Video

Updated: May 29, 2026

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Published on: December 8, 2023

Haploidentical hematopoietic transplantation: current status and future perspectives.

Yair Reisner¹, David Hagin, Massimo F Martelli

¹Department of Immunology, Weizmann Institute of Science, Rehovot, Israel. yair.reisner@weizmann.ac.il

|September 17, 2011

Summary

Hematopoietic stem cell transplantation using HLA-haploidentical donors overcomes major barriers like graft-versus-host disease (GVHD) and rejection. This approach now offers outcomes comparable to matched unrelated donor transplants for high-risk patients.

More Related Videos

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

Published on: February 16, 2024

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Published on: September 6, 2017

Related Experiment Videos

Last Updated: May 29, 2026

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Intrafemoral Injection of Human Hematopoietic Stem and Progenitor Cells into Immunocompromised Mice

Published on: December 8, 2023

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

In Vivo Osteo-organoid Approach for Harvesting Therapeutic Hematopoietic Stem/Progenitor Cells

Published on: February 16, 2024

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Detection of Residual Donor Erythroid Progenitor Cells after Hematopoietic Stem Cell Transplantation for Patients with Hemoglobinopathies

Published on: September 6, 2017

Area of Science:

Hematology
Immunology
Transplantation Medicine

Background:

Hematologic malignancies pose relapse risks, especially without matched stem cell donors.
HLA-haploidentical family donors offer a readily available alternative stem cell source.
Transplantation across major HLA barriers historically led to severe graft-versus-host disease (GVHD) and graft rejection.

Purpose of the Study:

To review advancements in overcoming obstacles in HLA-haploidentical transplantation.
To assess the current clinical reality and outcomes of full haplotype-mismatched transplantation.
To discuss current options, their pros and cons, and future strategies for post-transplant immunity and survival.

Main Methods:

Review of scientific literature over the last 15 years.
Analysis of strategies to mitigate T-cell alloreactions in HLA-mismatched transplantation.
Evaluation of current and innovative approaches for immune reconstitution and survival improvement.

Main Results:

Significant progress has been made in overcoming historical obstacles to HLA-haploidentical transplantation.
Full haplotype-mismatched transplantation is now a clinical reality with outcomes similar to matched unrelated donor transplants.
Current options and innovative strategies are improving survival and immune recovery.

Conclusions:

HLA-haploidentical transplantation is a viable and effective option for patients lacking matched donors.
Continued innovation is crucial for further improving outcomes and expanding the use of this transplantation method.
Understanding and managing T-cell alloreactions remains key to successful mismatched stem cell transplantation.